EFFICACY OF ERLOTINIB FOR CNS RELAPSE AFTER GEFITINIB TREATMENT IN NON SMALL CELL LUNG CANCER PATIENTS

被引：0
作者：
Yanagitani, N. [1 ]
Sakatani, T. [1 ]
Saito, R. [1 ]
Tanaka, H. [1 ]
Kaburaki, K. [1 ]
Kudo, K. [1 ]
Ohyanagi, F. [1 ]
Horiike, A. [1 ]
Horai, T. [1 ]
Nishio, M. [1 ]
机构：
[1] Japanese Fdn Canc Res, Thorac Oncol Ctr, Canc Inst Hosp, Tokyo, Japan
来源：
ANNALS OF ONCOLOGY | 2010年 / 21卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：155 / 156
页数：2
相关论文
共 50 条
  • [31] Gefitinib (G) treatment outcome after progression on erlotinib (E) in patients with advanced non-small-cell lung cancer (NSCLC)
    Grossi, F.
    Brianti, A.
    Defferrari, C.
    Dal Bello, M. G.
    Loprevite, M.
    Catania, G.
    Pronzato, P.
    EJC SUPPLEMENTS, 2007, 5 (04): : 395 - 395
  • [32] Gefitinib (G) treatment outcome after progression on erlotinib (E) in patients with advanced non-small cell lung cancer (NSCLC)
    Grossi, F.
    Brianti, A.
    Defferrari, C.
    Loprevite, M.
    Catania, G.
    Pronzato, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [33] Gefitinib (G) treatment outcome after progression on erlotinib (E) in patients with advanced non-small-cell lung cancer (NSCLC)
    Defferrari, C.
    Brianti, A.
    Dal Bello, M. G.
    Loprevite, M.
    Catania, G.
    Pronzato, P.
    Grossi, F.
    ANNALS OF ONCOLOGY, 2007, 18 : 24 - 24
  • [34] Cerebrospinal fluid concentration of gefitinib and erlotinib in patients with non-small cell lung cancer
    Yosuke Togashi
    Katsuhiro Masago
    Satohiro Masuda
    Tomoyuki Mizuno
    Masahide Fukudo
    Yasuaki Ikemi
    Yuichi Sakamori
    Hiroki Nagai
    Young Hak Kim
    Toshiya Katsura
    Michiaki Mishima
    Cancer Chemotherapy and Pharmacology, 2012, 70 : 399 - 405
  • [35] Comparison of gefitinib and erlotinib for Korean patients with advanced non-small cell lung cancer
    Lee, Jin Hwa
    Jo, You Ri
    Park, Hye Sung
    Ryu, Yon Ju
    Chun, Eun Mi
    Chang, Jung Hyun
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S692 - S692
  • [36] Successful Treatment of Non-small Cell Lung Cancer with Gefitinib after Severe Erlotinib-related Hepatotoxicity
    Kunimasa, Kei
    Yoshioka, Hiroshige
    Iwasaku, Masahiro
    Nishiyama, Akihiro
    Korogi, Yohei
    Masuda, Gen
    Takaiwa, Takuya
    Ishida, Tadashi
    INTERNAL MEDICINE, 2012, 51 (04) : 431 - 434
  • [37] CT findings in non-small-cell lung cancer patients treated with gefitinib or erlotinib
    Na, Im Il
    Choe, Du Hwan
    Kim, Cheol Hyeon
    Park, Sun Hoo
    Park, Jong Heon
    Lee, Jae Cheol
    JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2012, 8 (02) : 247 - 253
  • [38] Cerebrospinal fluid concentration of gefitinib and erlotinib in patients with non-small cell lung cancer
    Togashi, Yosuke
    Masago, Katsuhiro
    Masuda, Satohiro
    Mizuno, Tomoyuki
    Fukudo, Masahide
    Ikemi, Yasuaki
    Sakamori, Yuichi
    Nagai, Hiroki
    Kim, Young Hak
    Katsura, Toshiya
    Mishima, Michiaki
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 70 (03) : 399 - 405
  • [39] Erlotinib as salvage treatment after failure to first-line gefitinib in non-small cell lung cancer
    Matthew K. Wong
    Alvis I. Lo
    Bing Lam
    W. K. Lam
    Mary S. Ip
    James C. Ho
    Cancer Chemotherapy and Pharmacology, 2010, 65 : 1023 - 1028
  • [40] Efficacy of pemetrexed combined with erlotinib/gefitinib in advanced non-small cell lung cancer patients during tyrosine kinase inhibitor treatment
    Guanzhong Zhang
    Zhaozhe Liu
    Tao Han
    Xiaodong Xie
    Shunchang Jiao
    OncologyandTranslationalMedicine, 2017, 3 (03) : 93 - 98
12345